

## BLOOD PRODUCTS ADVISORY COMMITTEE

November 16-17, 2009

### REFERENCES

#### **Topic I. Blood Donor Deferral for Malaria Risk Associated with Travel to Mexico**

1. Leiby D et al. Impact of donor deferrals for malaria on blood availability in the United States. *Transfusion*. 2009; 48(10): 2222-2228.
2. Mungai M et al. Transfusion-transmitted malaria in the United States from 1963 through 1999. *NEJM*. 2001; 344(26):1973-8.
3. Spencer B. et al. Risk for malaria in United States donors deferred for travel to malaria-endemic areas. *Transfusion*. In Press. Published online July 2009.  
<http://www3.interscience.wiley.com/journal/122498698/abstract>

#### **Topic II. Study Designs (Phases 3 and 4) for Product Development of Human Platelets Using the Cerus INTERCEPT Blood System for Pathogen Inactivation**

1. Kerkhoffs JH et al. Clinical Effectiveness and Safety of Pooled, Random Donor Platelet Concentrates, Leucoreduced and Stored up to Seven Days in Either Plasma or Additive Solution with and Without Pathogen Reduction in Hemato-Oncological Patients. *Transfusion*. 2009; 49(s3): 2A. Abstract P5-020A.
2. Osselaer JC et al. An active haemovigilance programme characterizing the safety profile Of 7437 platelet transfusions prepared with amotosalen photochemical treatment. *Vox Sanguinis*. 2008; 94(4), 315-323.
3. Osselaer JC et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. *Transfusion*. 2009; 49(7):1412-22.
4. Silliman CC et. al. Transfusion-related acute lung injury (TRALI): Current concepts and misconceptions. *Blood Reviews*. In press. Published online August 2009.  
<http://www.sciencedirect.com/science/journal/0268960X>
5. Zarbock A and Ley K. The role of platelets in acute lung injury (ALI) *Frontiers in Bioscience*. 2009; 14: 150-158.

#### **Topic III. Blood Pressure and Pulse as Blood Donor Eligibility Criteria**

1. Ditto B et al. Effects of applied muscle tension on the likelihood of blood donor return. *Transfusion*. 2009 ; 49(5): 858-862.
2. Eder A et al. Selection criteria to protect the blood donor in North America and Europe: past (dogma), present (evidence), and future (hemovigilance). *Transfus Med Rev*. 2009; 23(3): 205-220.
3. Eder AF et al. The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. *Transfusion*. 2008; 48(9): 1809-19.
4. France CR et al. Donors who react may not come back: Analysis of repeat donation as a function of phlebotomist ratings of vasovagal reactions. *Transfusion and Apheresis Science*. 2005; 33(2): 99-106.
5. France CR et al. Psychometric properties of the Blood Donation Reactions Inventory: a subjective measure of presyncopal reactions to blood donation. *Transfusion*. 2008; 48(9): 1820-1826.

6. France CR, Menitove JE. Mitigating adverse reactions in youthful donors. Editorial. *Transfusion*. 2008; 48(9): 1774-1776.
7. Grindon AJ. Adverse reactions to whole blood donation and plasmapheresis. *Crit Rev Clin Lab Sci*. 1982; 17(1): 51-75.
8. Hanson SA, France CR. Predonation water ingestion attenuates negative reactions to blood donation. *Transfusion*. 2004; 44(6): 924-926.
9. Meade MA et al. Predicting Vasovagal Reactions in Volunteer Blood Donors. *J Psychosom Res*. 1996; 40(5): 495-501.
10. McLeod BC et al. Frequency of immediate adverse effects associated with apheresis donation. *Transfusion*. 1998; 38(10): 938-943.
11. Newman BH et al. The effect of whole-blood donor adverse events on blood donor return rates. *Transfusion*. 2006; 46(8): 1374-1379.
12. Newman BH. Vasovagal reaction rates and body weight: findings in high- and low-risk populations. *Transfusion*. 2003; 43(8): 1084-1088.
13. Pindyck J et al. Blood Donation by the Elderly: Clinical and Policy Considerations. *JAMA*. 1987; 257(9): 1186 - 1188.
14. Popovsky MA et al. Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. *Transfusion*. 1995; 35(9): 734-737.
15. Popovsky MA. Vasovagal donor reactions: An important issue with implications for the blood supply. Editorial. *Transfusion*. 2002; 42(12): 1534-1536.
16. Reiss RF et al. Rates of Vaso-Vagal Reactions Among First Time Teenaged Whole Blood, Double Red Cell, and Plateletpheresis Donors. *Annals of Clinical and Laboratory Science*. 2009; 39(2): 138-143.
17. Simon TL et al. Characteristics of elderly blood donors. *Transfusion*. 1991; 31(8): 693-697.
18. Tomasulo PA et al. A study of criteria for blood donor deferral. *Transfusion*. 1980; 20(5): 511-518.
19. Tomita T et al. Vasovagal reactions in apheresis donors. *Transfusion*. 2002; 42(12): 1561-1566.
20. Trouern-Trend JJ et al. A case-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. *Transfusion*. 1999;39(3): 316-20.
21. Wiltbank TB et al. Faint and prefaint reactions in whole-blood donors: an analysis of predonation measurements and their predictive value. *Transfusion*. 2008; 48(9): 1799-1808.
22. Winters JL. Complications of Donor Apheresis. *J. Clin. Apheresis*. 2006; 21(2): 132-141.

**Topic IV. Public Health Need and Performance Characteristics for Over-the-Counter Home-Use HIV Test Kits**

1. Meeting Minutes. Nov. 3-4, 2005. Blood Products Advisory Committee. [http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4190M1\\_quick%20minutes.htm](http://www.fda.gov/ohrms/dockets/ac/05/minutes/2005-4190M1_quick%20minutes.htm)
2. Meeting Minutes. March 9-10, 2006. Blood Products Advisory Committee. <http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4206M.htm>